• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    Ampio Pharmaceuticals, Inc. (AMPE)

    -NYSE MKT
    3.64 Up 0.07(1.96%) Dec 18, 4:05PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Ampio Pharmaceuticals, Inc.
    5445 DTC Parkway
    Suite 925
    Greenwood Village, CO 80111
    United States - Map
    Phone: 720-437-6500
    Fax: 720-437-6501
    Website: http://www.ampiopharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:16

    Business Summary 

    Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and decreasing vascular permeability. Its lead product candidates in development include Ampion, which is in Phase III clinical trial for osteoarthritis of the knee and Optina that is in Phase IIb clinical trial for diabetic macular edema. The company, through its subsidiaries, is also involved in the development and commercialization of RedoxSYS, an in-vitro diagnostic platform that measures human oxidation-reduction potential; and Zertane, an oral drug in late stage development as treatment for premature ejaculation in men. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ampio Pharmaceuticals, Inc.

    Corporate Governance 
    Ampio Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 4; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Michael MacAluso , 63
    Founder, Chairman and Chief Exec. Officer
    376.00K0.00
    Mr. Joshua R. Disbrow , 39
    Chief Operating Officer
    356.00K0.00
    Dr. David Bar-Or M.D. , 65
    Chief Scientific Officer and Director
    455.00K0.00
    Mr. Richard B. Giles , 65
    Director of Investor Relations, Director, Chairman of Audit Committee, Member of Nominating & Governance Committee and Member of Compensation Committee
    83.00KN/A
    Dr. Vaughan L. Clift M.D., 53
    Chief Regulatory Affairs Officer
    380.00K0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders